Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle

NDA FilingRhapsidoPositive

AI Analysis

Summary

Novartis announced that remibrutinib (Rhapsido) met its primary endpoint in a Phase 3 trial for relapsing multiple sclerosis, with plans to file for expanded approval by next year, positioning it as a competitor to Roche's fenebrutinib BTK inhibitor.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 trial met primary endpoint; expanded approval filing planned

Importance:7/10

Sentiment:

0.70

Phase 3BTK inhibitormultiple sclerosisregulatory filingcompetitive landscape

Related Companies

$NVS

Read the original article

Published by BioSpace on September 2, 2026 11:24 AM

Read Original